Heron Therapeutics Inc expected to post a loss of 1 cent a share - Earnings Preview

Heron Therapeutics

08/08/2025 15:15

Heron Therapeutics Inc HRTX.OQ HRTX.O is expected to  show a rise in quarterly revenue when it reports  results on August 11 for the period ending June 30 2025

The Cary North Carolina-based  company is expected to report a 16.0% increase in revenue to $39.488 million from $32.81 million a year ago, according to the mean estimate from 4 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Heron Therapeutics Inc is for a loss of 1 cent per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts had risen by about 50.0% in the last three months. ​

Wall Street's median 12-month price target for Heron Therapeutics Inc is $6.00, about 69.3% above its last closing price of $1.84

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.01
-0.01
-0.02
Missed
-100
Mar. 31 2025
-0.01
-0.01
0.01
Beat
175
Sep. 30 2024
-0.03
-0.03
0.02
Beat
10​
Jun. 30 2024
-0.03
-0.04
-0.03
Beat
10
​​Jun. 30 2024
-0.04
-0.04
-0.06
Missed
77.8
Mar. 31 2024
-0.16
-0.09
-0.02
Beat
77.8​
Dec. 31 2023
-0.16
-0.29
-0.17
Beat
57.2
Sep. 30 2023
-0.29
-0.23
-0.35
Missed
-50

This summary was machine generated August 8 at 14:15 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)